Pharmacokinetics, Tissue Distribution, Metabolism, and Excretion of Ginsenoside Rg1 in Rats

被引:49
作者
Feng, Liang [1 ]
Wang, Ling [2 ]
Hu, Changjiang [1 ]
Jiang, Xuehua [2 ]
机构
[1] Chengdu Univ TCM, Dept Pharm, State Key Lab Tradit Chinese Med, Chengdu 611137, Sichuan, Peoples R China
[2] Sichuan Univ, W China Ctr Med Sci, Dept Pharm, Chengdu 610041, Peoples R China
关键词
Ginsenosides Rg(1); LC-MS/MS; Pharmacokinetics; Tissue distribution; Metabolism; Excretion; PANAX-GINSENG; PHARMACOLOGY; SAPONINS;
D O I
10.1007/s12272-010-1213-2
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The pharmacokinetics, tissue distribution, metabolism, and excretion of ginsenosides Rg(1) were studied in Wistar rats, by measuring the concentrations of Rg(1) and its metabolites in the blood, tissues, bile, urine, and feces after dosing. After intravenous (i.v.) administration, the elimination half-lives of Rg(1) and its metabolites were 1.82, 5.87, and 6.87 h, and the area under the curves were 1595.7, 597.5, and 805.6 ng . h/mL, respectively. After oral administration, the elimination half-lives of Rg(1) and its metabolites were 2.25, 6.73, 5.44, and 5.06 h, and the area under the curves were 2363.5, 4185.5, 3774.3, and 396.2 ng . h/mL, respectively. After iv. administration, Rg(1) and its metabolites were well distributed to the tissues analyzed except for the brain. The maximum concentration of Rg(1) was reached in all tissues at 5 min post dose, and it was eliminated from most of the tissues except for the kidney faster than it was eliminated from the blood. The maximum concentration of the metabolites was reached in all tissues between 4 and 6 h post dose. After i.v. administration, the recovery of the Rg(1) prototype in the urine and bile was 27.96% and 60.77%, respectively. The metabolism of Rg(1) in the intestine was via a hydrolization pathway, with the 6-and 20-glucoside bond hydrolyzed gradually under the catalysis of beta-glucosaccharase, and then the metabolites were reabsorbed into the blood. Finally, the total recovery of the Rg(1) prototype and its metabolites in the urine and feces were 51.31% and 47.46%, respectively.
引用
收藏
页码:1975 / 1984
页数:10
相关论文
共 17 条
[1]   Ginseng pharmacology - Multiple constituents and multiple actions [J].
Attele, AS ;
Wu, JA ;
Yuan, CS .
BIOCHEMICAL PHARMACOLOGY, 1999, 58 (11) :1685-1693
[2]   Metabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities [J].
Bae, EA ;
Han, MJ ;
Choo, MK ;
Park, SY ;
Kim, DH .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2002, 25 (01) :58-63
[3]   Microbial transformation of 20(S)-protopanaxatriol-type saponins by Absidia coerulea [J].
Chen, Guangtong ;
Yang, Min ;
Lu, Zhiqiang ;
Zhang, Jinqiang ;
Huang, Huilian ;
Liang, Yan ;
Guan, Shuhong ;
Song, Yan ;
Wu, Lijun ;
Guo, De-an .
JOURNAL OF NATURAL PRODUCTS, 2007, 70 (07) :1203-1206
[5]   Panax ginseng pharmacology: A nitric oxide link? [J].
Gillis, CN .
BIOCHEMICAL PHARMACOLOGY, 1997, 54 (01) :1-8
[6]  
Han Min, 2006, Yao Xue Xue Bao, V41, P498
[7]   Main Ginseng saponin metabolites formed by intestinal bacteria [J].
Hasegawa, H ;
Sung, JH ;
Matsumiya, S ;
Uchiyama, M .
PLANTA MEDICA, 1996, 62 (05) :453-457
[8]   PANAX GINSENG AS A POTENTIAL IMMUNOMODULATOR - STUDIES IN MICE [J].
KIM, JY ;
GERMOLEC, DR ;
LUSTER, MI .
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 1990, 12 (02) :257-276
[9]   Ginsenoside-Rg1, one of the major active molecules from Panax ginseng, is a functional ligand of glucocorticoid receptor [J].
Lee, YJ ;
Chung, E ;
Lee, KY ;
Lee, YH ;
Huh, B ;
Lee, SK .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1997, 133 (02) :135-140
[10]  
Ma Y. Q., 1987, CHIN TRAD HERB DRUGS, V18, P21